During COVID-19 vaccine rollouts social media has been a breeding ground for anti-vaccine sentiments, which have led to vaccine hesitancy. This can increase vaccine-preventable diseases and create public health crises.
Health-related misinformation in social media has been shown to lead to poor health outcomes, including delayed treatment, unnecessary treatment, and wrong treatment. False information can spread rapidly: Social media platforms allow information to be shared quickly and widely, which means that false information can spread rapidly. This can result in a large number of people being exposed to incorrect information and acting on it, which can have serious consequences.
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
With this in mind, recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Now the Director of Infectious Diseases at Mater Health, Paul talks about coming into the field of infectious disease clinical trials, starting in malaria to now focusing on influenza, RSV and COVID-19 vaccines.
Paul reflects on the opportunity to learn and be involved in clinical trials from an early career stage and a turning point being in a senior role for a Phase 1 clinical study.
On the topic of misinformation in public health perception and literacy, Paul sees the issue continuing to circulate on the purpose of vaccines in general. This has also created hesitancy in ‘routine’ vaccine uptake.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.
Whilst the past 5 years may have improved public health literacy, it’s been outweighed by significant misinformation that does require an active campaign to encourage people to seek out information from reputable sources.
In closing, Paul talks about his advice for anyone looking to enter the field of clinical trials and vaccines: Early on, take the opportunities that arise, to be involved, help increase experience and new learning.
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
-
Medical research institutes association responds to draft national research strategy
On 27 August 2025, the Minister for Health, Disability and Ageing announced the release of the draft National Health and Medical Research Strategy (the National Strategy).
Involved in the initial consultation phase, was the Association of Australian Medical Research Institutes (AAMRI), the peak body for medical research institutes across Australia. Member institutes work on a broad spectrum of human health issues such as preventive health, chronic disease, mental health, immunology and Indigenous health. Their research ranges from fundamental biomedical discovery through to clinical research and the translation of research findings.
